Avo has closed a $10 million Series A round led by Noro-Moseley Partners, with participation from existing investors AlleyCorp, Las Olas Venture Capital, MedMountain Ventures, and Epsilon Health, alongside new investor Scrub Capital. Korean backers include Dunamu&Partners, which led two earlier rounds in 2021 and 2023, as well as Mirae Asset Capital and Futureplay.

The new capital will accelerate Avo’s push to become the leading AI platform for healthcare enterprises seeking to drive their most critical initiatives at the point of care.

The problem Avo is solving is a familiar one to anyone who has worked in a clinical setting: delivering high-quality care requires navigating dozens of tabs, applications, and disparate data sources — including rapidly evolving hospital protocols, medical guidelines, and payer policies that often live entirely outside the electronic health record (EHR). Avo sits at the center of that workflow, synthesizing patient data, proposing diagnoses and care plans, assisting with orders and documentation, and surfacing evidence-based guidance — all within the EHR. Its AI copilots, including Chart Assist and Ask Avo, support clinicians across end-to-end workflows like admission, discharge, and rounding.

“To truly save clinicians time with AI and do it in a way that health systems trust, we needed to build a flexible platform grounded in dependable evidence, comprehensive patient data, and tailored to the unique goals of our health system partners,” said Dr. Yair Saperstein, CEO and Co-Founder of Avo.

Avo was founded during the COVID-19 pandemic by Dr. Joongheum Park, now Executive Chairman and CPO, and Dr. Saperstein. Park, an internal medicine physician and clinical informatician, had grown frustrated by the sheer volume of medical knowledge and administrative overhead demanded of clinicians. The two co-founders met during a fellowship at Columbia University and teamed up to build a platform that would let clinicians practice evidence-based medicine without drowning in paperwork. Avo started as a no-code clinical application builder helping health systems operationalize their guidelines inside the EHR, then evolved into a full AI platform as large language models reshaped what was possible in healthcare. The platform now integrates with major EHR systems including Epic, athenahealth, and MEDITECH.

Avo has also attracted partnerships with major evidence-based organizations. MCG Health and KDIGO have both integrated select knowledge bases into the platform. In the latest development, Avo is partnering with EBSCO Clinical Decisions, the company behind DynaMed — a market leader in evidence-based clinical decision support — to bring its expert-curated knowledge base directly into the platform. Clinicians will be able to receive patient-specific, guideline-aligned recommendations without ever leaving the EHR.

“Clinicians want quick access to high-quality medical information that’s relevant to the patient in front of them,” said Allen Powell, CEO of EBSCO. “By integrating DynaMed into the Avo platform, we’re ensuring the most current, trusted knowledge is delivered in context and under the governance health systems expect.”

Avo’s results back up the pitch: $11.6 million in cost savings for a multinational ambulatory organization, a 35% reduction in per-patient note time at a large inpatient hospital, $7.5 million in incremental annual reimbursement from clinical documentation improvement at an academic medical center, a 28% increase in completed outpatient encounters across primary care clinics, and a 35% improvement in high-risk medication dosing compliance at a large national urgent care organization.

Investors see Avo as well-positioned for a market in transition. “The clinical decision support market is at an inflection point. Avo is uniquely positioned to lead this next wave by delivering real-time, actionable intelligence within the EHR with a demonstrable ROI,” said Ryan Collins, Principal at Noro-Moseley Partners.